CYP17 polymorphisms and prostate cancer outcomes.

Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, Ostrander EA, Stanford JL. CYP17 polymorphisms and prostate cancer outcomes. Prostate. 2010 Jul 01; 70(10):1094-101.

View in: PubMed

subject areas

Adult
Case-Control Studies
Cohort Studies
Disease Progression
DNA, Neoplasm
Genetic Predisposition to Disease
Genetic Variation
Genotype
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Polymerase Chain Reaction
Polymorphism, Single Nucleotide
Proportional Hazards Models
Prostatic Neoplasms
SEER Program
Steroid 17-alpha-Hydroxylase
Washington

authors with profiles

Daniel Lin

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement